Adrenomed AG
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB (NCT03085758) | Adrenomed AG | 2017-12-12 |
| Adrecizumab-LPS Study (NCT03083171) | Adrenomed AG | 2017-01-04 |
Track Adrenomed AG automatically
Every clearance here is in the API, with alerts when new ones post.